Q-omics provides the consensus-scored RNY1P13 profile across patient tissues and cancer cell-line models. RNY1P13 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RNY1P13 is differentially expressed in 7, with the highest sampling consensus in BLCA. Additionally, RNY1P13 RNA expression shows 16,270 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight THCA, BLCA, and DLBC as cancer lineages where RNY1P13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNY1P13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNY1P13 survival associations across molecular data types. RNY1P13 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNY1P13 RNA expression–survival associations across cancer types. High RNY1P13 expression shows unfavorable associations in THCA, OV, LGG and UVM, but favorable associations in LAML and HNSC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for RNY1P13 RNA expression.
This table summarizes RNY1P13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNY1P13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNY1P13 shows lower tumor expression in READ and higher tumor expression in BLCA, STAD, KIRP, PRAD and KIRC. The BLCA box plot shows higher RNY1P13 RNA expression in tumor versus normal tissue (log2 FC = +0.956, t-test p < 0.001).
This table shows molecular features associated with RNY1P13 in patient tissues and cancer cell lines. In patient samples, RNY1P13 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
